Literature DB >> 23899564

Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding.

Kendra N Iskander1, Marcin F Osuchowski, Deborah J Stearns-Kurosawa, Shinichiro Kurosawa, David Stepien, Catherine Valentine, Daniel G Remick.   

Abstract

Sepsis represents the host's systemic inflammatory response to a severe infection. It causes substantial human morbidity resulting in hundreds of thousands of deaths each year. Despite decades of intense research, the basic mechanisms still remain elusive. In either experimental animal models of sepsis or human patients, there are substantial physiological changes, many of which may result in subsequent organ injury. Variations in age, gender, and medical comorbidities including diabetes and renal failure create additional complexity that influence the outcomes in septic patients. Specific system-based alterations, such as the coagulopathy observed in sepsis, offer both potential insight and possible therapeutic targets. Intracellular stress induces changes in the endoplasmic reticulum yielding misfolded proteins that contribute to the underlying pathophysiological changes. With these multiple changes it is difficult to precisely classify an individual's response in sepsis as proinflammatory or immunosuppressed. This heterogeneity also may explain why most therapeutic interventions have not improved survival. Given the complexity of sepsis, biomarkers and mathematical models offer potential guidance once they have been carefully validated. This review discusses each of these important factors to provide a framework for understanding the complex and current challenges of managing the septic patient. Clinical trial failures and the therapeutic interventions that have proven successful are also discussed.

Entities:  

Mesh:

Year:  2013        PMID: 23899564      PMCID: PMC3962548          DOI: 10.1152/physrev.00037.2012

Source DB:  PubMed          Journal:  Physiol Rev        ISSN: 0031-9333            Impact factor:   37.312


  453 in total

Review 1.  Antibiotic use in the elderly: issues and nonissues.

Authors:  J D McCue
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

2.  Human recombinant interleukin-1 alpha protection against the lethality of endotoxin and experimental sepsis in mice.

Authors:  H R Alexander; G M Doherty; D L Fraker; M I Block; J E Swedenborg; J A Norton
Journal:  J Surg Res       Date:  1991-05       Impact factor: 2.192

Review 3.  The difficulties of clinical trials evaluating therapeutic agents in patients with severe sepsis.

Authors:  T C Hall; D K Bilku; D Al-Leswas; C Horst; A R Dennison
Journal:  Ir J Med Sci       Date:  2011-11-08       Impact factor: 1.568

4.  Human recombinant lactoferrin for sepsis: too good to be true?.

Authors:  Russell McCulloh; Steven M Opal
Journal:  Crit Care Med       Date:  2013-03       Impact factor: 7.598

5.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Authors:  S M Opal; C J Fisher; J F Dhainaut; J L Vincent; R Brase; S F Lowry; J C Sadoff; G J Slotman; H Levy; R A Balk; M P Shelly; J P Pribble; J F LaBrecque; J Lookabaugh; H Donovan; H Dubin; R Baughman; J Norman; E DeMaria; K Matzel; E Abraham; M Seneff
Journal:  Crit Care Med       Date:  1997-07       Impact factor: 7.598

6.  Analysis of progression in risk, injury, failure, loss, and end-stage renal disease classification on outcome in patients with severe sepsis and septic shock.

Authors:  Won Young Kim; Jin Won Huh; Chae-Man Lim; Younsuck Koh; Sang-Bum Hong
Journal:  J Crit Care       Date:  2011-06-28       Impact factor: 3.425

7.  Evaluation of definitions for sepsis.

Authors:  W A Knaus; X Sun; O Nystrom; D P Wagner
Journal:  Chest       Date:  1992-06       Impact factor: 9.410

8.  Computational modeling with forward and reverse engineering links signaling network and genomic regulatory responses: NF-kappaB signaling-induced gene expression responses in inflammation.

Authors:  Shih Chi Peng; David Shan Hill Wong; Kai Che Tung; Yan Yu Chen; Chun Cheih Chao; Chien Hua Peng; Yung Jen Chuang; Chuan Yi Tang
Journal:  BMC Bioinformatics       Date:  2010-06-08       Impact factor: 3.169

9.  Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone.

Authors:  Masatoshi Inden; Yoshihisa Kitamura; Hiroki Takeuchi; Takashi Yanagida; Kazuyuki Takata; Yuka Kobayashi; Takashi Taniguchi; Kanji Yoshimoto; Masahiko Kaneko; Yasunobu Okuma; Takahiro Taira; Hiroyoshi Ariga; Shun Shimohama
Journal:  J Neurochem       Date:  2007-06       Impact factor: 5.372

10.  Impact of HIV/AIDS on care and outcomes of severe sepsis.

Authors:  Joseph M Mrus; LeeAnn Braun; Michael S Yi; Walter T Linde-Zwirble; Joseph A Johnston
Journal:  Crit Care       Date:  2005-09-27       Impact factor: 9.097

View more
  143 in total

1.  Redox signaling and splicing dependent change in myosin phosphatase underlie early versus late changes in NO vasodilator reserve in a mouse LPS model of sepsis.

Authors:  John J Reho; Xiaoxu Zheng; Laureano D Asico; Steven A Fisher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-27       Impact factor: 4.733

2.  Female mice exhibit less renal mitochondrial injury but greater mortality using a comorbid model of experimental sepsis.

Authors:  Lee Ann MacMillan-Crow; Philip R Mayeux
Journal:  Intern Med Rev (Wash D C)       Date:  2018-10

3.  Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials.

Authors:  Carolyn S Calfee; Kevin Delucchi; Polly E Parsons; B Taylor Thompson; Lorraine B Ware; Michael A Matthay
Journal:  Lancet Respir Med       Date:  2014-05-19       Impact factor: 30.700

Review 4.  Enteric immunity, the gut microbiome, and sepsis: Rethinking the germ theory of disease.

Authors:  Javier Cabrera-Perez; Vladimir P Badovinac; Thomas S Griffith
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-04

5.  Circulatory effects of dexmedetomidine in early sepsis: a randomised controlled experimental study.

Authors:  Zoi Aidoni; Chryssa Pourzitaki; Eleni Stamoula; Katerina Kotzampassi; Georgia Tsaousi; George Kazakos; Christophoros N Foroulis; Charisios Skourtis; Dimitrios G Vasilakos; Vassilios Grosomanidis
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-08-17       Impact factor: 3.000

Review 6.  Utilizing melatonin to combat bacterial infections and septic injury.

Authors:  Wei Hu; Chao Deng; Zhiqiang Ma; Dongjin Wang; Chongxi Fan; Tian Li; Shouyin Di; Bing Gong; Russel J Reiter; Yang Yang
Journal:  Br J Pharmacol       Date:  2017-03-21       Impact factor: 8.739

7.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

Review 8.  The pediatric sepsis biomarker risk model: potential implications for sepsis therapy and biology.

Authors:  Matthew N Alder; Christopher J Lindsell; Hector R Wong
Journal:  Expert Rev Anti Infect Ther       Date:  2014-04-22       Impact factor: 5.091

9.  The STAT4/MLL1 Epigenetic Axis Regulates the Antimicrobial Functions of Murine Macrophages.

Authors:  William F Carson; Karen A Cavassani; Elyara M Soares; Soichiro Hirai; Nicolai A Kittan; Matthew A Schaller; Melissa M Scola; Amrita Joshi; Akihiro Matsukawa; David M Aronoff; Craig N Johnson; Yali Dou; Katherine A Gallagher; Steven L Kunkel
Journal:  J Immunol       Date:  2017-07-21       Impact factor: 5.422

Review 10.  Somato-Autonomic Reflexes of Acupuncture.

Authors:  Qiufu Ma
Journal:  Med Acupunct       Date:  2020-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.